Iron Sucrose
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Iron Sucrose: From Iron Deficiency Anaemia to Primary Hyperoxaluria
One-Sentence Summary
Iron sucrose is an intravenous iron replacement agent, generally used to treat iron deficiency anaemia. The TxGNN model predicts it may be effective for primary hyperoxaluria, but this is a graph-based prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Iron deficiency anaemia (general known use; the SAHPRA registration data provided do not state an indication) |
| Predicted New Indication | Primary hyperoxaluria |
| TxGNN Prediction Score | 98.82% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not currently available. Iron sucrose is an intravenous iron replacement agent. Its efficacy in iron deficiency anaemia is established, but no data link it mechanistically to primary hyperoxaluria.
Primary hyperoxaluria is a metabolic disorder of oxalate overproduction. The provided data identify no iron-related pathway that would plausibly affect it. The high TxGNN score (98.82%) reflects patterns in the knowledge graph, not confirmed biology. No trials or publications were retrieved to support or test the prediction.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. A 50/2.6.5/0687 | Innofer Injection | Injection | Not listed in the data provided |
| Reg. No. 45/8.3/0550 | Zypiron 20 | Injection | Not listed in the data provided |
Both registered products are injectable. Essential Medicines List (EML) status was not available in the data provided.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
The other nine TxGNN candidates were also screened. Preclinical studies for pancreatitis (rank 2) point toward harm, not benefit. High dietary iron and intravenous iron preparations caused pancreatic islet injury, beta cell death and pancreatitis in animal and in vitro models. This is not a primary hyperoxaluria finding, but it is a safety signal to review before any repurposing work on iron sucrose.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (L5). No clinical trials, literature or mechanistic link support iron sucrose for primary hyperoxaluria.
To proceed, the following is needed:
- SAHPRA Professional Information (package insert) warnings and contraindications. This is a blocking gap that prevents safety screening.
- Mechanism of action data (for example from DrugBank) to test whether any biological link to oxalate metabolism exists.
- Any preclinical or clinical evidence for iron sucrose in primary hyperoxaluria.
- Review of the preclinical pancreatic injury signal before any further consideration of this drug for new uses.
These results are for research reference only and do not constitute medical advice. Repurposing candidates require clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.